GDC 0276
Alternative Names: GDC-0276; RG-7893Latest Information Update: 04 Jun 2021
At a glance
- Originator Xenon Pharmaceuticals
- Developer Genentech; Xenon Pharmaceuticals
- Class Non-opioid analgesics; Small molecules
- Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 31 Dec 2020 Xenon Pharmaceuticals and Genentech has patent pending for GDC 0276 in the US
- 31 Dec 2020 Xenon Pharmaceuticals and Genentech has patent pending for GDC 0276 in the various jurisdictions
- 31 Dec 2020 Xenon Pharmaceuticals and Genentech has patent protection for GDC 0276 in the foreign countries (exclusive of European patent national validations)